BACKGROUND: The increased diuresis after sodium-glucose cotransporter 2 inhibitor (SGLT2i) was associated with a reduction of the estimated plasma volume (ePV) in type 2 diabetic patients. HYPOTHESIS: We hypothesized that the early effect of SGLT2i on ePV may be monitored by the change of biomarkers of hemoconcentration. PATIENTS AND METHODS: We analyzed the early- and long-term effect of SGLT2i empagliflozin on the ePV as assessed by biomarkers of hemoconcentration in a nondiabetic patient with heart failure and reduced ejection fraction (HFrEF) and a nondiabetic patient with heart failure and preserved ejection fraction (HFpEF). The ePV was calculated from hemoglobin and hematocrit levels by Duarte formula and ePV change was calculated by Strauss formula. RESULTS: The ePV change was -22.56% between baseline and 1 month, and -37.60% between baseline and 12 months follow-up in a patient with HFrEF, and -6.18% and -16.40% in a patient with HFpEF, respectively. CONCLUSION: The early effect of SGLT2i on ePV in patients with heart failure may be monitored by biomarkers of hemoconcentration.

3rd Faculty of Medicine Charles University Prague Czech Republic

Center of Nuclear Medicine Faculty Hospital Bulovka Prague Czech Republic

Na Homolce Hospital Prague Czech Republic

See more in PubMed

Zinman B., Wanner C., Lachin J. M., et al., “Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes,” New England Journal of Medicine 373, no. 22 (2015): 2117–2128. PubMed

Neal B., Perkovic V., Mahaffey K. W., et al., “Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes,” New England Journal of Medicine 377 (2017): 644–657. PubMed

Wiviott S. D., Raz I., Bonaca M. P., et al., “Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes,” New England Journal of Medicine 380 (2019): 347–357. PubMed

McMurray J. J. V., Solomon S. D., Inzucchi S. E., et al., “Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction,” New England Journal of Medicine 381 (2019): 1995–2008. PubMed

Packer M., Anker S. D., Butler J., et al., “Cardiovascular and Renal Outcomes With Empagliflozin in Heart Failure,” New England Journal of Medicine 383, no. 15 (2020): 1413–1424. PubMed

Anker S. D., Butler J., Filippatos G., et al., “Empagliflozin in Heart Failure With a Preserved Ejection Fraction,” New England Journal of Medicine 385 (2021): 1451–1461. 10.1056/NEJMoa2107038. PubMed DOI

Solomon S. D., McMurray J. J. V., Claggett B., et al., “Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction,” New England Journal of Medicine 387 (2022): 1089–1098. PubMed

Mcdonagh T. A., Metra M., Adamo M., et al., “2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). With the Special Contribution of the Heart Failure Association (HFA) of the ESC,” European Journal of Heart Failure 24 (2022): 4–131. PubMed

Heidenreich P. A., Bozkurt B., Aguilar D., et al., “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation 145 (2022): e895–e1032. PubMed

McDonagh T. A., Metra M., Adamo M., et al., “2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure,” European Heart Journal 44, no. 37 (2023): 3627–3639. PubMed

Joshi S. S., Singh T., Newby D. E., and Singh J., “Sodium‐Glucose Co‐transporter 2 Inhibitor Therapy: Mechanisms of Action in Heart Failure,” Heart 107 (2021): 1032–1038. PubMed PMC

Dekkers C. C. J., Sjöström C. D., Greasley P. J., Cain V., Boulton D. W., and Heerspink H. J. L., “Effects of the Sodium‐Glucose Co‐transporter‐2 Inhibitor Dapagliflozin on Estimated Plasma Volume in Patients With Type 2 Diabetes,” Diabetes, Obesity and Metabolism 21 (2019): 2667–2673. PubMed PMC

Matsubayashi Y., Yoshida A., Suganami H., et al., “Association of Estimated Plasma Volume and Weight Loss After Long‐Term Administration and Subsequent Discontinuation of the Sodium‐Glucose Cotransporter‐2 Inhibitor Tofogliflozin,” Diabetes, Obesity and Metabolism 23 (2021): 1660–1665. PubMed PMC

Pabel S., Hamdani N., Luedde M., and Sossalla S., “SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?” Current Heart Failure Reports 18 (2021): 315–328. PubMed PMC

Mentz R. J., Kjeldsen K., Rossi G. P., et al., “Decongestion in Acute Heart Failure,” European Journal of Heart Failure 16 (2014): 471–482. PubMed PMC

Duarte K., Monnez J. M., Albuisson E., Pitt B., Zannad F., and Rossignol P., “Prognostic Value of Estimated Plasma Volume in Heart Failure,” JACC: Heart Failure 3 (2015): 886–893. PubMed